Tumor Microenvironment Specific Regulation Ca‐Fe‐Nanospheres for Ferroptosis‐Promoted Domino Synergistic Therapy and Tumor Immune Response
Small · 2024
DOI: 10.1002/smll.202312141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Xu Chu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Separation Membranes and Membrane Processes & Key Laboratory of Hollow Fiber Membrane Materials and Membrane Processes (MOE),…. Hauptthemen laut MEDLINE: Ferroptosis, Tumor Microenvironment, Calcium, Reactive Oxygen Species. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin, Science and Technology Plans of Tianjin.
Abstract (Originalsprache)
Reactive oxygen species (ROS)‐mediated emerging treatments exhibit unique advantages in cancer therapy in recent years. While the efficacy of ROS‐involved tumor therapy is greatly restricted by complex tumor microenvironment (TME). Herein, a dual‐metal CaO 2 @CDs‐Fe (CCF) nanosphere, with TME response and regulation capabilities, are proposed to improve ROS lethal power by a multiple cascade synergistic therapeutic strategy with domino effect. In response to weak acidic TME, CCF will decompose, accompanied with intracellular Ca 2+ upregulated and abundant H 2 O 2 and O 2 produced to reverse antitherapeutic TME. Then the exposed CF cores can act as both Fenton agent and sonosensitizer to generate excessive ROS in the regulated TME for enhanced synergistic CDT/SDT. In combination with calcium overloading, the augmented ROS induced oxidative stress will cause more severe mitochondrial damage and cellular apoptosis. Furthermore, CCF can also reduce GPX4 expression and enlarge the lipid peroxidation, causing ferroptosis and apoptosis in parallel. These signals of damage will finally initiate damage‐associated molecular patterns to activate immune response and to realize excellent antitumor effect. This outstanding domino ROS/calcium loading synergistic effect endows CCF with excellent anticancer effect to efficiently eliminate tumor by apoptosis/ferroptosis/ICD both in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Separation Membranes and Membrane Processes & Key Laboratory of Hollow Fiber Membrane Materials and Membrane Processes (MOE), School of Material Science and Engineering & School of Chemistry, Tia…
- School of Electronic and Information Engineering & School of Chemical Engineering and Technology, Tiangong University, Tianjin, 300387, P. R. China.
- School of Chemical and Environmental Engineering, Wuhan Polytechnic University, Wuhan, 430023, P. R. China.
- Hubei Key Laboratory of Radiation Chemistry and Functional Materials, School of Nuclear Technology and Chemistry and Biology, Hubei University of Science and Technology, Xianning, 437100, China.
ORCID-Profile: Shu-Lan Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin
- Science and Technology Plans of Tianjin
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Chu, X., Hou, H. Y., Duan, M. D., Zhang, Y. J., Zhu, Y. Y., Liu, Y., & Li, S. L. (2024). Tumor Microenvironment Specific Regulation Ca‐Fe‐Nanospheres for Ferroptosis‐Promoted Domino Synergistic Therapy and Tumor Immune Response. Small. https://doi.org/10.1002/smll.202312141
Vancouver
Chu X, Hou HY, Duan MD, Zhang YJ, Zhu YY, Liu Y, et al. Tumor Microenvironment Specific Regulation Ca‐Fe‐Nanospheres for Ferroptosis‐Promoted Domino Synergistic Therapy and Tumor Immune Response. Small. 2024. doi:10.1002/smll.202312141
BibTeX
@article{Chu2024,
author = {Chu, Xu and Hou, Hua-Ying and Duan, Meng-Die and Zhang, Yu-Juan and Zhu, Yu-Ying and Liu, Yi and Li, Shu-Lan},
title = {Tumor Microenvironment Specific Regulation Ca‐Fe‐Nanospheres for Ferroptosis‐Promoted Domino Synergistic Therapy and Tumor Immune Response},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202312141}
}
EUVIMED